Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Decision makers have huge problems when attempting to attribute social value to the improvements achieved by new drugs, especially when considering the use of orphan drugs for rare diseases. We present the results of a pilot study aimed to investigate patient preferences regarding public funding for drugs used to treat rare diseases.
Pubmed ID: 31242905
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
A Software resource for statistical analysis and presentation of graphics.
View all literature mentions